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• Multidrug resistant (MDR) infections are 
associated with high mortality and limited 
treatment options1-3
• The characteristics of MDR organisms that 
present to Lehigh Valley Health Network 
(LVHN) are unknown
• Infection control guidelines encourage 
partnerships between inpatient and outpatient 
health care facilities to better control the 
spread of these high-risk infections6
Non-Healthcare Facility
• Determine the characteristics and treatment 
of MDR organisms among patients admitted 
to LVHN
• Identify common admission and discharge 
locations for patients admitted to LVHN 
diagnosed with a MDR organism • Contact most common admission and 
discharge facilities to determine their infection 
control practices
• Develop partnerships between LVHN and 
most frequent outpatient facilities
• Establish a standardized approach to 
infection control practices among inpatient 
and outpatient health care facilities with 





Assessment of the Characteristics of Multidrug Resistant Organisms at Lehigh Valley Health Network: 
Where Do They Come From and Where Do They Go?
Courtney Landis, Amy Slenker MD, Jarrod Kile RPh. BCPS, Luther Rhodes MD
Methods
• Retrospective chart review of 371 adult 
patient encounters (237 unique patients) at 
LVH-CC and LVH-M identified with a MDR 
organism in 2018
• Obtain patient demographics, admission and 
discharge locations and dates, empiric and 
targeted antibiotic days of treatment, and 
results of positive MDR culture(s) from the 




























Median Number of Days (IQR)
Empiric DOT 1 (0-3)
Targeted DOT in Hospital 2 (0-5)
Total Planned Targeted DOT 4.5 (0-10)
Total Antibiotic DOT 7 (3-14)
Hospital Length of Stay 6 (4-11)
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Table 1: Days of Therapy (DOT) for MDR Organism Infections
Figure 3: Characteristics of MDR Organisms at LVHN
*Includes long term care, short term hospital, 
and left against medical device.
SNF, skilled nursing facility; ALF, assisted 
living facility; IRC, inpatient rehab center
TSU, transitional skilled unit
*Includes Proteus and Citrobacter.
ESBL, extended spectrum beta-
lactamase; VRE, vancomycin-









• The most common MDR organism and 
source at LVHN is ESBL E. coli in urine
• While most patients are admitted and 
discharged to non-healthcare facilities 
(Figures 1 and 2), the vast majority of MDR 
organisms are still healthcare-associated 
(94%)
• Facilities external to LVHN with the greatest 
incidence of MDR organisms are ManorCare, 
Fellowship Manor, Valley Manor, and Phoebe 
(Figures 1 and 2)
• LVHN is treating these infections 
appropriately, with a median of only 1 empiric 
DOT and a median of 7 total DOT
